logo

Abstract B195: Lorvotuzumab mertansine displays favorable

If you want to confirm some technical details before you order,
just need to send a message or e-mail: [email protected].
Then our professional sales staff will contact you within 2 hours.

Selective Tumor Targeting of Desacetyl Vinblastine Hydrazide and Tubulysin B via Conjugation to a Cholecystokinin 2 Receptor (CCK2R) Ligand .

Comparative in vivo efficacy tests confirmed that, like EC140, EC145 displays activity against both syngeneic and xenograft tumor models. However, EC145 was found to be more active and better tolerated than EC140; hence, ...

ENGINEERED POLYPEPTIDES AND USES THEREOF - VISTERRA, IN

A monoclonal antibody composition displays a single binding specificity and affinity for a particular ... Analysis of sub-networks informs introduction of synergistic mutations for favorable FcRn interaction; with reduced or minimal impact on other Fc residues. ...

CA2861932A1 - Chromatographic media for storage and delivery of therapeutic biologics and small molecules - Google Paten

Described are composite materials and methods of making and using them for the storage and delivery of unstable drugs or biologies. In certain embodiments, the composite material comprises a support member, comprising a plurality of pores extending through ...

WO2017189961A1 - Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors - Google Paten

Described herein are nanoparticle conjugates that demonstrate enhanced penetration of tumor tissue (e.g., brain tumor tissue) and diffusion within the tumor interstitium, e.g., for treatment of cancer. Further described are methods of targeting tumor-associated ...

ADME of Antibody–Maytansinoid Conjugates | SpringerLi

Sun X, C. L, Ellis M, Whiteman KR, Pinkas J, Lazar A, Erickson H. Lorvotuzumab mertansine displays favorable pharmacokinetics and tumor delivery in mouse models. AACR-NCI-EORTC Abstract # B195. 2011. Google Scholar 51. Erickson HK, P. C, Mayoet al ...

WO2017189961A1 - Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors - Google Paten

Described herein are nanoparticle conjugates that demonstrate enhanced penetration of tumor tissue (e.g., brain tumor tissue) and diffusion within the tumor interstitium, e.g., for treatment of cancer. Further described are methods of targeting tumor-associated ...

IJMS | Free Full-Text | Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update | HT

in heavily pre-treated RRMM subjects while the drug’s safety profile was very favorable. Moreover, ... The ADC lorvotuzumab mertansine (HuN901-DM1; IMGN901; BB-10901) represents an anti-NCAM humanized IgG1 mAb linked to a maytansine A ...

Targeting CD56 (NCAM)-Expressing Neoplasms with Lorvotuzumab Mertansine | SpringerLi

CD56, also known as neural cell adhesion molecule (NCAM), is a type 1 transmembrane glycoprotein that is expressed on neuronal tissue, skeletal and heart muscle, various cells of neuroendocrine... ... Abstract CD56, also known as neural cell adhesion ...

Molecules | Free Full-Text | Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy | HT

A full-length antibody having a long circulation half-life leading to a good chance of reaching the tumor site is thus favorable for an ADC. ... Lorvotuzumab mertansine (IMGN901) Phase II Hematologic-blood cancer, sarcoma, neuroblastoma, SCLC, MM CD56 SPP ...

A review of soft-tissue sarcomas: translation of biological advances into treatment measures (pdf) | Paperi

See also TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare... TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities Incidence of Sarcoma Histotypes and Molecular ...

ADME of Antibody–Maytansinoid Conjugat

Sun X, C. L, Ellis M, Whiteman KR, Pinkas J, Lazar A, Erickson H. Lorvotuzumab mertansine displays favorable pharmacokinetics and tumor delivery in mouse models. AACR-NCI-EORTC Abstract # B195. 2011. 51. Erickson HK, P. C, Mayo MF, Widdison WC. ...

[Full text] A review of soft-tissue sarcomas: translation of biological advances i | CM

Ngoc T Hoang, * Luis A Acevedo, * Michael J Mann, Bhairavi Tolani Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA * These authors contributed equally to this ...

Selective Tumor Targeting of Desacetyl Vinblastine Hydrazide and Tubulysin B via Conjugation to a Cholecystokinin 2 Receptor (CCK2R) Ligand .

Comparative in vivo efficacy tests confirmed that, like EC140, EC145 displays activity against both syngeneic and xenograft tumor models. However, EC145 was found to be more active and better tolerated than EC140; hence, ...

Abstract B195: Lorvotuzumab mertansine displays favorable pharmacokinetics and tumor delivery in mouse models. | Molecular Cancer Therapeuti

Abstract Lorvotuzumab mertansine (LM) is an antibody-drug conjugate consisting of three components: a monoclonal antibody, lorvotuzumab, that binds specifically to the CD56 antigen expressed on several types of cancers; a potent maytansinoid cell-killing agent ...

Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cel

A phase 2 trial evaluating lorvotuzumab-mertansine is ongoing (NCT02452554). Therefore, it can be concluded that using ADCs to deplete the stemness properties of CSCs by targeting ligands on the CSC cell surface may improve the impact of conventional ...

Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? - ScienceDire

Lorvotuzumab Mertansine Table 3. Selected completed and ongoing trials of bispecific antibodies, DARTs, TRiKEs Drug Molecular target ...

Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? - ScienceDire

Lorvotuzumab Mertansine Table 3. Selected completed and ongoing trials of bispecific antibodies, DARTs, TRiKEs Drug Molecular target ...

CA2861932A1 - Chromatographic media for storage and delivery of therapeutic biologics and small molecules - Google Paten

Described are composite materials and methods of making and using them for the storage and delivery of unstable drugs or biologies. In certain embodiments, the composite material comprises a support member, comprising a plurality of pores extending through ...

Antibodies | Free Full-Text | Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under .

Antibodies | Free Full-Text | Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under ...

Abstract 4576: IMGN853, an anti-Folate Receptor I antibody-maytansinoid conjugate for targeted cancer therapy | Olga Ab | Request P

Request PDF on ResearchGate | Abstract 4576: IMGN853, an anti-Folate Receptor I antibody-maytansinoid conjugate for targeted cancer therapy | Previously we reported (O. Ab; EORTC, 2010) that an antibody-maytansinoid conjugate (AMC) composed of an anti ...